News
DYN
17.61
+0.40%
0.07
A Look At Dyne Therapeutics (DYN) Valuation After New CNS Tauopathy Data And Pipeline Expansion Potential
Simply Wall St · 1d ago
Trump plans to fire FDA commissioner Marty Makary, WSJ reports
TipRanks · 2d ago
Dyne Therapeutics director Jason P. Rhodes disposes of common shares worth $1.94 million
PUBT · 3d ago
Weekly Report: what happened at DYN last week (0427-0501)?
Weekly Report · 6d ago
A Look At Dyne Therapeutics (DYN) Valuation After New MAPT Blood Brain Barrier Data
Simply Wall St · 05/01 19:53
Dyne Therapeutics director Jason P. Rhodes disposes of shares worth $4.18 million
PUBT · 04/30 22:02
Could Dyne Therapeutics (DYN) Turn Its FORCE Platform Into a Broader Neurology Franchise?
Simply Wall St · 04/30 03:14
Dyne Therapeutics Director Jason P. Rhodes disposes of $6.76 million in shares
PUBT · 04/27 22:16
Dyne to present primate data showing FORCE platform crosses blood-brain barrier
PUBT · 04/27 20:34
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
Barchart · 04/27 15:34
Weekly Report: what happened at DYN last week (0420-0424)?
Weekly Report · 04/27 10:33
Dyne director Dirk Kersten reports DYN share sale worth $219,364
PUBT · 04/23 20:17
Dyne Therapeutics grants inducement awards to 18 new employees under Nasdaq rule
PUBT · 04/23 20:11
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 04/23 15:05
Dyne Therapeutics director Dirk Kersten disposes of USD 6.8 million common shares
PUBT · 04/21 20:17
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating
TipRanks · 04/21 10:15
Weekly Report: what happened at DYN last week (0413-0417)?
Weekly Report · 04/20 10:28
Dyne director Dirk Kersten disposes of $2,021,419 Dyne Therapeutics shares
PUBT · 04/17 20:05
Dyne Therapeutics Advances Pivotal DYNE-101 Trial in Myotonic Dystrophy Type 1
TipRanks · 04/16 16:32
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
TipRanks · 04/13 19:35
More
Webull provides a variety of real-time DYN stock news. You can receive the latest news about Dyne Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.